Effects of canagliflozin on weight loss in high-fat diet-induced obese mice

PLoS ONE

Volumn 12, Issue 6, 2017, Pages

  Ji, Wenjun ^a,b   Zhao, Mei ^a,c   Wang, Meng ^a,d   Yan, Wenhui ^a   Liu, Yuan ^a   Ren, Shuting ^a   Lu, Jun ^a   Wang, Bing ^a   Chen, Lina ^a  

^a XI'AN JIAOTONG UNIVERSITY   (China)

^b TAIZHOU PEOPLE S HOSPITAL   (China)

^c BEIJING 302 HOSPITAL   (China)

^d Shijiazhuang Maternity Hospital   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ACYLTRANSFERASE; CANAGLIFLOZIN; CHOLESTEROL; DIACYLGYCEROL ACYLTRANSFERASE 2; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA 2; SODIUM GLUCOSE COTRANSPORTER; TETRAHYDROLIPSTATIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; ANTIDIABETIC AGENT; DGAT2 PROTEIN, MOUSE; DIACYLGLYCEROL ACYLTRANSFERASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG MEGADOSE; FATTY LIVER; LIPID DIET; LIVER INJURY; LIVER MORPHOLOGY; LIVER WEIGHT; LOW DRUG DOSE; MALE; MORPHOLOGY; MOUSE; NONHUMAN; OBESITY; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT REDUCTION; ANIMAL; BLOOD; C57BL MOUSE; DRUG EFFECTS; ENZYMOLOGY; LIVER; METABOLISM; PATHOLOGY;

ANIMALS; CANAGLIFLOZIN; CHOLESTEROL; DIACYLGLYCEROL O-ACYLTRANSFERASE; DIET, HIGH-FAT; HYPOGLYCEMIC AGENTS; LIVER; MICE; MICE, INBRED C57BL; OBESITY; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS; TRIGLYCERIDES; WEIGHT LOSS;

EID: 85021690949     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0179960     Document Type: Article

References (28)

1. Malik VS, Popkin BM, Bray GA, Despres JP, Hu FB. Sugar-sweetened beverages, obesity, type 2 diabetes mellitus, and cardiovascular disease risk. Circulation. 2010; 121: 1356–1364. https: //doi.org/10.1161/CIRCULATIONAHA.109.876185 PMID: 20308626
2. Ginsberg HN, MacCallum PR. The obesity, metabolic syndrome, and type 2 diabetes mellitus pandemic: Part I. Increased cardiovascular disease risk and the importance of atherogenic dyslipidemia in persons with the metabolic syndrome and type 2 diabetes mellitus. J Cardiometab Syndr. 2009; 4: 113–119. https: //doi.org/10.1111/j.1559-4572.2008.00044.x PMID: 19614799
3. Obesity and overweight. Geneva (Switzerland): World Health Organization; 2014. Available: www.who.int/mediacentre/factsheets/fs311/en/
4. Krentz AJ, Fujioka K, Hompesch M. Evolution of pharmacological obesity treatments: focus on adverse side-effect profiles. Diabetes Obes Metab. 2016; 18: 558–570. https: //doi.org/10.1111/dom.12657 PMID: 26936802
5. Blasio A, Rice KC, Sabino V, Cottone P. Characterization of a shortened model of diet alternation in female rats: effects of the CB1 receptor antagonist rimonabant on food intake and anxiety-like behavior. Behav Pharmacol. 2014; 25: 609–617. https: //doi.org/10.1097/FBP.0000000000000059 PMID: 25011007
6. Padwal RS, Majumdar SR. Drug treatments for obesity: orlistat, sibutramine, and rimonabant. Lancet. 2007; 369: 71–77. https: //doi.org/10.1016/S0140-6736(07)60033-6 PMID: 17208644
7. Palacios-Martinez D, Garcia-Alvarez JC, Montero-Santamaria N, Villar-Ruiz OP, Ruiz-Garcia A, Diaz-Alonso RA. Macrocytic anemia and thrombocytopenia induced by orlistat. Int J Endocrinol Metab. 2013; 11: e6721. https: //doi.org/10.5812/ijem.6721 PMID: 24719628
8. Liang Y, Arakawa K, Ueta K, Matsushita Y, Kuriyama C, Martin T, Du F, Liu Y, Xu J, Conway B, et al. Effect of canagliflozin on renal threshold for glucose, glycemia, and body weight in normal and diabetic animal models. Plos One. 2012; 7: e30555. https: //doi.org/10.1371/journal.pone.0030555 PMID: 22355316
9. Jin Y, McFie PJ, Banman SL, Brandt C, Stone SJ. Diacylglycerol acyltransferase-2 (DGAT2) and monoacylglycerol acyltransferase-2 (MGAT2) interact to promote triacylglycerol synthesis. J Biol Chem. 2014; 289: 28237–28248. https: //doi.org/10.1074/jbc.M114.571190 PMID: 25164810
10. Gu M, Fan S, Liu G, Guo L, Ding X, Lu Y, Zhang Y, Ji G, Huang C. Extract of Wax Gourd Peel Prevents High-Fat Diet-Induced Hyperlipidemia in C57BL/6 Mice via the Inhibition of the PPARgamma Pathway. Evid Based Complement Alternat Med. 2013; 2013: 342561. https: //doi.org/10.1155/2013/342561 PMID: 23533476
11. Qin YW, Ye P, He JQ, Sheng L, Wang LY, Du J. Simvastatin inhibited cardiac hypertrophy and fibrosis in apolipoprotein E-deficient mice fed a "Western-style diet" by increasing PPAR alpha and gamma expression and reducing TC, MMP-9, and Cat S levels. Acta Pharmacol Sin. 2010; 31: 1350–1358. https: //doi.org/10.1038/aps.2010.109 PMID: 20835264
12. McFie PJ, Banman SL, Kary S, Stone SJ. Murine diacylglycerol acyltransferase-2 (DGAT2) can catalyze triacylglycerol synthesis and promote lipid droplet formation independent of its localization to the endoplasmic reticulum. J Biol Chem. 2011; 286: 28235–28246. https: //doi.org/10.1074/jbc.M111. 256008 PMID: 21680734
13. Boyle LD, Wilding JP. A safety evaluation of canagliflozin: a first-in-class treatment for type 2 diabetes. Expert Opin Drug Saf. 2014; 13: 1535–1544. https: //doi.org/10.1517/14740338.2014.959488 PMID: 25340618
14. Wilding JP, Charpentier G, Hollander P, González-Gálvez G, Mathieu C, Vercruysse F, Usiskin K, Law G, Black S, Canovatchel W, Meininger G. Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial. Int J Clin Pract. 2013; 67: 1267–1682. https: //doi.org/10.1111/ijcp.12322 PMID: 24118688
15. Liang Y, Arakawa K, Ueta K, Matsushita Y, Kuriyama C, Martin T, Du F, Liu Y, Xu J, Conway B, et al. Effect of canagliflozin on renal threshold for glucose, glycemia, and body weight in normal and diabetic animal models. Plos One. 2012; 7: e30555. https: //doi.org/10.1371/journal.pone.0030555 PMID: 22355316
16. Triplitt C, Cornell S. Canagliflozin Treatment in Patients with Type 2 Diabetes Mellitus. Clin Med Insights Endocrinol Diabetes. 2015; 8: 73–81. https: //doi.org/10.4137/CMED.S31526 PMID: 26523120
17. Haque M, Sanyal AJ. The metabolic abnormalities associated with non-alcoholic fatty liver disease. Best Pract Res Clin Gastroenterol. 2002; 16: 709–731. PMID: 12406441
18. Xu A, Wang Y, Keshaw H, Xu LY, Lam KS, Cooper GJ. The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. J Clin Invest. 2003; 112: 91–100. https: //doi.org/10.1172/JCI17797 PMID: 12840063
19. Milagro FI, Campion J, Martinez JA. Weight gain induced by high-fat feeding involves increased liver oxidative stress. Obesity (Silver Spring). 2006; 14: 1118–1123.
20. Gao BZ, Chen JC, Liao LH, Xu JQ, Lin XF, Ding SS. Erchen Decoction Prevents High-Fat Diet Induced Metabolic Disorders in C57BL/6 Mice. Evid Based Complement Alternat Med. 2015; 2015: 501272. https: //doi.org/10.1155/2015/501272 PMID: 26504476
21. Kim HJ, Kang CK, Park H, Lee MG. Effects of vitamin D supplementation and circuit training on indices of obesity and insulin resistance in T2D and vitamin D deficient elderly women. J Exerc Nutrition Bio-chem. 2014; 18: 249–257. https: //doi.org/10.5717/jenb.2014.18.3.249 PMID: 25566461
22. You DY, Wu ZY, Wan JX, Cui J, Zou ZH. Analysis of renal functions and proteinuria in young obese adults. J Endocrinol Invest. 2015; 38: 901–908. https: //doi.org/10.1007/s40618-015-0272-0 PMID: 25833358
23. Honda Y, Imajo K, Kato T, Kessoku T, Ogawa Y, Tomeno W, Kato S, Mawatari H, Fujita K, Yoneda M, et al. The selective SGLT2 inhibitor ipragliflozin has a therapeutic effect on nonalcoholic steatohepatitis in mice. Plos One. 2016; 11: e146337.
24. Komiya C, Tsuchiya K, Shiba K, Miyachi Y, Furuke S, Shimazu N, Yamaguchi S, Kanno K, Ogawa Y. Ipragliflozin Improves Hepatic Steatosis in Obese Mice and Liver Dysfunction in Type 2 Diabetic Patients Irrespective of Body Weight Reduction. Plos One. 2016; 11: e151511.
25. Honda Y, Imajo K, Kato T, Kessoku T, Ogawa Y, Tomeno W, Kato S, Mawatari H, Fujita K, Yoneda M, et al. The Selective SGLT2 Inhibitor Ipragliflozin Has a Therapeutic Effect on Nonalcoholic Steatohepa-titis in Mice. Plos One. 2016; 11: e146337.
26. McFie PJ, Banman SL, Kary S, Stone SJ. Murine diacylglycerol acyltransferase-2 (DGAT2) can catalyze triacylglycerol synthesis and promote lipid droplet formation independent of its localization to the endoplasmic reticulum. J Biol Chem. 2011; 286: 28235–28246. https: //doi.org/10.1074/jbc.M111. 256008 PMID: 21680734
27. Takahashi N, Senda M, Lin S, Goto T, Yano M, Sasaki T, Murakami S, Kawada T. Auraptene regulates gene expression involved in lipid metabolism through PPARalpha activation in diabetic obese mice. Mol Nutr Food Res. 2011; 55: 1791–1797. https: //doi.org/10.1002/mnfr.201100401 PMID: 22038981
28. Ross PK, Woods CG, Bradford BU, Kosyk O, Gatti DM, Cunningham ML, Rusyn I. Time-course comparison of xenobiotic activators of CAR and PPARalpha in mouse liver. Toxicol Appl Pharmacol. 2009; 235: 199–207. https: //doi.org/10.1016/j.taap.2008.12.011 PMID: 19136022